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Secretory glycoproteins that fail to fold or assemble
correctly are retained in the endoplasmic reticulum and
eventually degraded. Recent evidence shows that
trimming of their N-linked oligosaccharide chains plays
a key role in targeting glycoproteins for destruction.
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Secretory glycoproteins begin their life in the endoplasmic
reticulum (ER). In the ER environment, nascent polypep-
tides undergo co-translational signal peptide cleavage and
N-linked glycosylation, disulfide bonds are formed and
the proteins acquire their mature tertiary and quaternary
structures. A number of resident molecular chaperones
and enzymes help the maturation processes: for example,
the ER molecular chaperones BiP, Grp94, calnexin and
calreticulin bind to nascent polypeptides and increase
their efficiency of folding and assembly; the ER enzyme
protein disulfide isomerase (PDI) catalyses the formation
of intrachain and interchain disulfide bridges.
To ensure that only structurally mature and properly assem-
bled proteins are allowed to reach their final destination
— secretion, the plasma membrane or subcompartments
of the secretory pathway — the ER employs a number of
‘quality control’ mechanisms [1]. These mechanisms
monitor the folding and oligomerisation state of secretory
proteins, and provide further assistance to polypeptides
that have not yet achieved their correct structure. Quality
control allows only correctly folded and assembled pro-
teins to leave the ER; immature, permanently misfolded
or unassembled proteins are retained in the ER and even-
tually degraded. Recent studies have shed new light on
the role of oligosaccharide processing in targeting for
degradation glycoproteins that, for one reason or another,
fail to mature properly [2,3].
The best known example of a quality control mechanism
operating in the ER on newly synthesized glycoproteins is
the calnexin–calreticulin cycle [4]. N-linked oligosaccha-
rides are attached to newly synthesized proteins in the
ER (Figure 1). The oligosaccharides undergo rapid trim-
ming of two of the three glucose residues by ER glucosi-
dases I and II. Calnexin and calreticulin are lectin
chaperones which, acting in a complex with the lumenal
oxidoreductase Erp57 [5], bind to monoglucosylated gly-
coproteins and promote their folding. The proteins are
then released and their remaining glucose residue is
removed by glucosidase II. If the proteins are correctly
folded, they are permitted to leave the ER. If, however,
folding is incomplete, the glycoproteins are recognised by
the enzyme UDP–glucose:glycoprotein glucosyltransferase
(UGT), which re-glucosylates their oligosaccharides,
allowing the proteins to undergo a new cycle of calnexin
binding. UGT therefore functions as a real folding
sensor, by determining which proteins are structurally
sound and which ones require further rounds of interac-
tion with calnexin.
Figure 1
Schematic structure of the N-linked core oligosaccharide added to
polypeptides in the ER. The arrows indicate the sites of action of ER-
located glucosidases (G) and mannosidases (ERM). Dotted lines
indicate the site of action of the inhibitors of glycan processing
enzymes mentioned in the text: CST, castanospermine; dMJ,
deoxymannojirimycin; Kif, kifunensine; Swn, swainsonine.
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It seems that, in the ER, every protein is given a good
chance to mature properly. In some cases, nevertheless, a
protein can fail to mature. Proteins that are terminally
misfolded, as a result of mutation, cellular stress [6] or
viral infection [7], or unassembled subunits of multimeric
proteins, such as the T-cell receptor [8,9], are singled out
by the quality control system and retained inside the ER,
mostly by interactions with chaperones, and eventually
targeted for degradation. In recent years, the nature of
this degradation process, commonly referred to as ER-asso-
ciated degradation (ERAD), has been the subject of
intense investigation. It is now accepted that the cytosolic
26S proteasome is the ultimate site of degradation of
ER-located defective proteins or orphan protein subunits
[10]. There is evidence, both in yeast and mammalian
cells, that condemned proteins are dislocated from the
ER to the cytosol through the Sec61 translocon and
degraded by the proteasome. Once in the cytosol, pro-
teins can be deglycosylated and/or ubiquitinated prior to
proteasomal disposal.
Although the proteasome is the most popular destination
for ERAD substrates, recent reports suggest that cytoplas-
mic disposal might not be the only route of degradation for
defective proteins. Degradation of partially folded human
glycoprotein thyroperoxidase, for example, seems to be
dependent on cysteine and serine proteases associated with
the ER membrane [11]. Similarly, the regulated turnover
of wild-type, non-glycosylated membrane proteins, such
as HMG-coenzyme A reductase and stearoyl-coenzyme A
desaturase, appears also to depend on ER membrane-
associated proteases [12,13]. Furthermore, there is evi-
dence that proteases in the ER lumen might be involved
in degradation of human P-glycoprotein [14]. Much work
is needed to elucidate further these alternative prote-
olytic pathways.
How are misfolded glycoproteins recognised as such and
targeted for ERAD? Recent evidence indicates that the
structure of the N-linked glycans, resulting from the action
of various glycosidases resident in the ER (Figure 1), can
influence the efficiency of targeting of glycoproteins to
proteolysis in the cytoplasm [15,16]. This suggests that
there is some form of conformational sensing of protein-
bound sugars, and this is likely to involve the lectin
chaperones, such as calnexin and calreticulin, and the ER
oligosaccharide-processing enzymes. In particular, a
number of recent reports seem to suggest a key role for
the ER mannosidases.
De Virgilio et al. [17] recently showed that a truncated
form of the ribophorin — an ERAD substrate — in which
glycosylation sites were removed was degraded in vivo
with faster kinetics than the glycosylated form. An analo-
gous effect was observed when glycosylated ribophorin
was synthesised in the presence of castanospermine, a
drug that inhibits glucose trimming (Figure 1) and there-
fore prevents binding to calnexin. This suggests that
Figure 2
A model for the integration of the calnexin cycle,
glycan trimming and disposal routes in the
quality control of glycoproteins (modified from
[1]). Newly synthesised, monoglucosylated
glycoproteins enter the calnexin (CNX) cycle;
when folded correctly, their mannoses are
trimmed by mannosidases (ERMI and ERMII)
and the proteins leave the ER. If proteins are
misfolded or unassembled, they are targeted to
dislocation from the ER and proteasomal
degradation by two possible mechanisms.
(a) Targeting for degradation occurs in the
absence of calnexin binding (for example, when
cells are treated with castanospermine), but
requires mannose trimming [2]. (b) Mannose
trimming to Man8 leads to a prolonged
interaction of the unfolded proteins with
calnexin, because the Man8 oligosaccharide is
a poor substrate for glucosidase II (GII).
Extended interaction with calnexin eventually
leads to dislocation and proteasomal
degradation [3,16]. In the case of the PI Z
variant of human α1-antitrypsin, further mannose
trimming to Man7 partitions the protein away
from the calnexin cycle, and therefore
proteasomal degradation, and targets PI Z to a
novel proteolytic route that can be inhibited by
tyrosine phosphatase inhibitors (TPI).
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association with calnexin retards degradation. Treatment
with inhibitors of ER mannosidases, such as 1-deoxyman-
nojirimycin, greatly stabilised ribophorin, suggesting that
mannose trimming is required for degradation [17]. 
Similarly, treatment with castanospermine resulted in faster
degradation of class I major histocompatibility complex
(MHC) heavy chains in a mammalian semipermeabilised
cell system [2]. The same effect was also observed with
semi-permeabilised cells from a mutant cell line lacking cal-
nexin, again suggesting that calnexin interaction prolongs
the lifetime of a misfolded protein. Treatment with either
castanospermine or 1-deoxymannojirimycin inhibited degra-
dation, showing that mannose trimming of the glycan is the
crucial step required to target MHC class I heavy chains for
proteolysis, independently of calnexin binding [2]. Reduced
degradation on inhibition of ER mannosidase activity has
also been observed for other mammalian ERAD substrates,
such as unassembled CD3 δ subunits of the T cell receptor
[9] and misfolded α1-antitrypsin [16], and for carboxypepti-
dase Y in mannosidase-deficient yeast strains [15]. 
The emerging picture from all this evidence is that
mannose trimming is sufficient to regulate the half-life
and the ultimate fate of glycoproteins in the ER
(Figure 2). An alternative interpretation, based on studies
with α1-antitrypsin, is that the number of mannose
residues on the oligosaccharide chain affects the efficiency
of binding and release from calnexin: when the glycan is
in the GlcNAc2Man8Glc1 form — a poor substrate for
glucosidase II — dissociation from calnexin is retarded
and the prolonged interaction with calnexin per se could
sequester the glycoprotein from the folding pathway and
target it for degradation [16]. 
In their recent paper, Cabral et al. [3] provide additional
evidence to support this controversial interpretation.
Several defective variants of α1-antitrypsin are targeted by
the proteasome after prolonged interaction with calnexin.
But Cabral et al. [3] found that the PI Z variant of α1-antit-
rypsin is degraded in vivo by a process that does not
involve the proteasome. Degradation of PI Z could be
blocked by inhibitors of tyrosine phosphatase activity,
such as sodium pervanadate. It appears that PI Z is a sub-
strate for the non-proteasomal proteolytic pathway only
when its glycan has been processed to the GlcNAc2Man7
form, which is no longer a suitable substrate for calnexin
binding. When cells are treated with inhibitors of the ER
mannosidases, such as kifunensine or swainsonine, so that
PI Z is locked into the calnexin cycle, the protein is
degraded by the proteasome and its degradation can be
inhibited by the proteasome-specific inhibitor lactacystin,
as previously shown for other α1-antitrypsin variants [16].
When castanospermine was added post-translationally,
once again locking PI Z in the calnexin cycle, degradation
was similarly performed by the proteasome [3]. But when
castanospermine was added co-translationally, thus inhibit-
ing all glucose removal and preventing PI Z from binding
calnexin at all, the protein was found to be degraded by
the non-proteasomal pathway [3]. Simultaneous use of
castanospermine and 1-deoxymannojirimycin, as in the
experiments of Wilson et al. [2], would be required to
determine whether calnexin binding is really needed to
target PI Z for proteasomal degradation. Nevertheless, the
data reported by Cabral et al. [3] indicate that, in the case
of PI Z, mannose trimming of the oligosaccharide chain,
whilst still acting as a regulator for calnexin binding, also
plays a role in sorting PI Z to different degradative path-
ways. Identifying the nature of the non-proteasomal degra-
dation pathway will be an exciting goal for future work.
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